Usefulness of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19 (IVERCAR)

Carvallo et al., NCT04425850, NCT04425850

Oct 2020

Source PDF All Studies Meta AnalysisMeta

Prophylaxis study using ivermectin and carrageenan showing 0 of 131 cases from treated healthcare workers, compared to 11 of 98 control.

The effect is likely to be primarily due to ivermectin - the author has later reported that carrageenan is not necessary youtube.com.

See doyourownresearch.substack.com for discussion of issues with this trial.

5 studies use direct respiratory tract administration Aref, Aref (B), Carvallo, Carvallo (B), Chahla

Targeted administration to the respiratory tract provides treatment directly to the typical source of initial SARS-CoV-2 infection and replication, and allows for rapid onset of action, higher local drug concentration, and reduced systemic side effects.

This is the 13th of 99 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 2 sextillion). 46 studies are RCTs, which show efficacy with p=0.00000014.

This study is excluded in the after exclusion results of meta analysis: concern about potential data issues.

1. Aref et al., Possible Role of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Recovery of Post-COVID-19 Anosmia, Infection and Drug Resistance, doi:10.2147/IDR.S381715.dovepress.com, doi.org.

2. Aref (B) et al., Clinical, Biochemical and Molecular Evaluations of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Reducing Upper Respiratory Symptoms of Mild COVID-19, International Journal of Nanomedicine, doi:10.2147/IJN.S313093.dovepress.com, doi.org.

3. Carvallo et al., Study of the Efficacy and Safety of Topical Ivermectin + Iota-Carrageenan in the Prophylaxis against COVID-19 in Health Personnel, Journal of Biomedical Research and Clinical Investigation, doi:10.31546/2633-8653.1007.medicalpressopenaccess.com, doi.org.

4. Carvallo (B) et al., Usefulness of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19 (IVERCAR), NCT04425850, clinicaltrials.gov/ct2/show/results/NCT04425850.clinicaltrials.gov.

5. Chahla et al., Intensive Treatment With Ivermectin and Iota-Carrageenan as Pre-exposure Prophylaxis for COVID-19 in Health Care Workers From Tucuman, Argentina, American Journal of Therapeutics, doi:10.1097/MJT.0000000000001433.lww.com, doi.org.

6. doyourownresearch.substack.com, doyourownresearch.substack.com/p/the-potemkin-argument-part-vii-together.doyourownresearch.substack.com/p/the-potemkin-argument-part-vii-together.

7. youtube.com, www.youtube.com/watch?v=CB6Bvi_g-w8.www.youtube.com/watch?v=CB6Bvi_g-w8.

Important missing comments or errors? Let us know.

risk of case, 96.3% lower, RR 0.04, p < 0.001, treatment 0 of 131 (0.0%), control 11 of 98 (11.2%), NNT 8.9, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Carvallo et al., 19 Oct 2020, prospective, Argentina, preprint, 1 author, dosage 1mg days 1-14, this trial uses multiple treatments in the treatment arm (combined with iota-carrageenan) - results of individual treatments may vary, trial NCT04425850 (history).

All Studies Meta Analysis Submit Updates or Corrections

This Paper Ivermectin All

Download Image

Please send us corrections, updates, or comments. c19early involves the extraction of over 100,000 datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

@CovidAnalysis

FAQ

Public domain CC0 1.0